CV6 Therapeutics Strengthens Scientific Advisory Board with Recent Appointments

CV6 Therapeutics Strengthens Scientific Advisory Board with Recent Appointments

17th May 2018

Belfast, U.K. – May 17, 2018.

CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of two new members to their Scientific Advisory Board.

Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, UK. Paul is a leader in the field of molecularly targeted cancer drugs and his research focus is the discovery and development new treatments that exploit our knowledge of the cancer genome and cancer biology toward the goal of personalised medicine. Paul has been instrumental in progressing more than 20 cancer drugs into clinical trials, including inhibitors of hsp90, PI3K and cell cycle checkpoint proteins and is Co-founder of Piramed Pharma and Chroma Therapeutics.

Ruth Plummer, MD, Professor of Experimental Cancer Medicine at the Newcastle University (UK) and Director of the Sir Bobby Robson Cancer Trials Research Centre. Ruth is an expert in the field of DNA repair and early phase clinical trials of novel agents, taking the first in class PARP, ATR and MCT1 inhibitors into the clinic.

“Our Scientific Advisory Board will be instrumental in helping us drive forward our expanding pipeline of therapeutic assets. Their guidance and insight will be invaluable as we prioritise and develop our programs,” stated Robert Ladner, Ph.D., Chief Executive Officer of CV6 Therapeutics.

Find out more

CV6 Therapeutics

CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, click here: CV6 Therapeutics.